137 related articles for article (PubMed ID: 33917514)
1. Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition.
Park JJ; Diefenbach RJ; Byrne N; Long GV; Scolyer RA; Gray ES; Carlino MS; Rizos H
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917514
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
3. Detection of metastases using circulating tumour DNA in uveal melanoma.
Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.
de Bruyn DP; van Poppelen NM; Brands T; van den Boom SC; Eikenboom E; Wagner A; van Veghel-Plandsoen MM; Geeven G; Beverloo B; van Rij CM; Verdijk RM; Naus NC; Bagger MM; Kiilgaard JF; de Klein A; Brosens E; Kiliç E
Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):11. PubMed ID: 38319670
[TBL] [Abstract][Full Text] [Related]
5. Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma.
Beasley A; Isaacs T; Khattak MA; Freeman JB; Allcock R; Chen FK; Pereira MR; Yau K; Bentel J; Vermeulen T; Calapre L; Millward M; Ziman MR; Gray ES
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913999
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.
Forschner A; Weißgraeber S; Hadaschik D; Schulze M; Kopp M; Kelkenberg S; Sinnberg T; Garbe C; Biskup S; Battke F
Onco Targets Ther; 2020; 13():5017-5032. PubMed ID: 32581559
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Kim C; Xi L; Cultraro CM; Wei F; Jones G; Cheng J; Shafiei A; Pham TH; Roper N; Akoth E; Ghafoor A; Misra V; Monkash N; Strom C; Tu M; Liao W; Chia D; Morris C; Steinberg SM; Bagheri H; Wong DTW; Raffeld M; Guha U
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283064
[No Abstract] [Full Text] [Related]
10. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.
Wong SQ; Raleigh JM; Callahan J; Vergara IA; Ftouni S; Hatzimihalis A; Colebatch AJ; Li J; Semple T; Doig K; Mintoff C; Sinha D; Yeh P; Silva MJ; Alsop K; Thorne H; Bowtell DD; Gyorki DE; Arnau GM; Cullinane C; Kee D; Brady B; Kelleher F; Dawson MA; Papenfuss AT; Shackleton M; Hicks RJ; McArthur GA; Sandhu S; Dawson SJ
JCO Precis Oncol; 2017 Nov; 1():1-14. PubMed ID: 35172485
[TBL] [Abstract][Full Text] [Related]
13. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients.
Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K
Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
16. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
17. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
19. Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach RJ; Lee JH; Menzies AM; Carlino MS; Long GV; Saw RPM; Howle JR; Spillane AJ; Scolyer RA; Kefford RF; Rizos H
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32785074
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.
Braune J; Keller L; Schiller F; Graf E; Rafei-Shamsabadi D; Wehrle J; Follo M; Philipp U; Hussung S; Pfeifer D; Mix M; Duyster J; Fritsch R; von Bubnoff D; Meiss F; von Bubnoff N
JCO Precis Oncol; 2020 Nov; 4():20-31. PubMed ID: 35050727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
